NVIV - InVivo Therapeutics Holdings Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

InVivo Therapeutics Holdings Corp.

One Kendall Square
Floor 4 Building 1400 East
Cambridge, MA 02139
United States

Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard M. ToselliPres, CEO, Chief Medical Officer & DirectorN/AN/A1958
Dr. Robert S. Langer Jr.Co-Founder and Member of Scientific Advisory BoardN/AN/A1949
Dr. Joseph Philip VacantiCo-FounderN/AN/A1949
Mr. Jeffrey ModestinoPrincipal Financial Officer, Principal Accounting Officer & TreasurerN/AN/AN/A
Mr. William D'Agostino PESr. VP of OperationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

InVivo Therapeutics Holdings Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.